Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry

British Journal of Haematology
Howard TerebeloCONNECT MM Registry Investigators

Abstract

Median overall survival (OS) has improved for patients with newly diagnosed multiple myeloma (NDMM), but prognosis varies depending on baseline patient characteristics. Current models use data from selected clinical trial populations, which prevent application to patients in an unselected community setting that reflects routine clinical practice. Using data from the Connect® MM Registry, a large, US, multicentre, prospective observational cohort study (Cohort 1: 2009-2011; Cohort 2: 2012-2016) of 3011 patients with NDMM, we identified prognostic variables for OS via the multivariable analysis of baseline patient characteristics in Cohort 1 (n = 1493) and developed a tool to examine individual outcomes. Factors associated with OS (n = 1450 treated patients; P < 0·05) were age, del(17p), triplet therapy use, EQ-5D mobility, International Staging System stage, solitary plasmacytoma, history of diabetes, platelet count, Eastern Cooperative Oncology Group performance status and serum creatinine, which were used to create survival matrices for 3- and 5-year OS. The model was internally and externally validated using Connect MM Cohort 2 (Harrell's concordance index, 0·698), MM-015 (0·649), and the phase 3 FIRST (0·647) clinical trials...Continue Reading

Associated Clinical Trials

References

Jan 1, 1989·American Journal of Epidemiology·R M Mickey, S Greenland
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Sep 30, 2005·European Journal of Haematology·Athanasios AnagnostopoulosMeletios-Athanasios Dimopoulos
Oct 11, 2005·Mayo Clinic Proceedings·S Vincent Rajkumar, Robert A Kyle
Jun 6, 2007·Prevention Science : the Official Journal of the Society for Prevention Research·John W GrahamTamika D Gilreath
Jul 11, 2007·Statistical Methods in Medical Research·Stef van Buuren
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Dec 18, 2008·Source Code for Biology and Medicine·Zoran BursacDavid W Hosmer
Mar 25, 2010·Journal of the National Comprehensive Cancer Network : JNCCN·Ashraf Z Badros
May 25, 2010·Seminars in Oncology·Susan Halabi, Kouros Owzar
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joan L WarrenGregory A Abel
May 27, 2014·American Society of Clinical Oncology Educational Book·P Leif Bergsagel
Sep 4, 2014·The New England Journal of Medicine·Lotfi BenboubkerUNKNOWN FIRST Trial Team
Jan 27, 2015·Clinical Lymphoma, Myeloma & Leukemia·Robert M RifkinBrian G M Durie
Aug 5, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboPhilippe Moreau
Jan 15, 2016·Mayo Clinic Proceedings·S Vincent Rajkumar, Shaji Kumar
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
Jun 14, 2016·American Journal of Hematology·S Vincent Rajkumar
Dec 23, 2016·Leukemia·R FonsecaP Richardson
Feb 17, 2017·Therapeutic Advances in Hematology·Shahzad RazaSuzanne Lentzsch
Mar 23, 2017·Advances in Hematology·Amr HanbaliFahad Alsharif
Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study
May 26, 2017·American Journal of Hematology·Howard TerebeloJatin J Shah
Jul 7, 2017·Blood·Jean Luc Harousseau, Michel Attal
Jul 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip L McCarthyMichel Attal
Nov 28, 2017·Journal of Biopharmaceutical Statistics·Gaohong DongMarc Vandemeulebroecke
May 3, 2018·Journal of the National Cancer Institute·Daniel W Cramer, Kevin M Elias

❮ Previous
Next ❯

Methods Mentioned

BETA
ISS

Clinical Trials Mentioned

NCT01081028

Software Mentioned

ISS
NDMM
R
EveryFit

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.